Peiwen Yu entered into an agreement to acquire 48.3% stake in Entest Group, Inc. (OTCPK:ETNI) from Regen BioPharma, Inc. (OTCPK:RGBP), Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust for $0.33 million on November 15, 2018. Under the terms of the deal, Peiwen Yu will acquire 23.7 million shares of common stock, 667 shares of Series AA preferred stock, 534 shares of Series AAA Preferred Stock and approximately 1 million shares of Non-Voting Convertible Preferred Stock, of Entest. On the closing date, Peiwen Yu shall pay the amount of $0.33 million, $0.03 million of which shall be continue to be held in the escrow account subsequent to the closing. Prior to the transaction, Regen BioPharma held 8 million common stock and 0.19 million of the Non-Voting Convertible Preferred Stock of Entest Group.

Regen BioPharma will receive $0.05 million from sale of the common stock and $1,858.52 from the sale of the Non-Voting Convertible Preferred Stock. The escrow agreement requires that David R. Koos shall resign as Director and Officer of Entest Group, Inc. to be replaced by nominees of the purchaser of the securities. Richard I. Anslow of Ellenoff Grossman & Schole LLP acted as legal advisor to Peiwen Yu.

McMurdo Law Group, LLC acted as escrow agent in the transaction.